Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02674893
Other study ID # BRINDISI 2013
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date February 4, 2014
Est. completion date August 31, 2016

Study information

Verified date September 2019
Source Centre Hospitalier Universitaire Dijon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label comparative study in three parallel groups. It is expected that 90 patients and/or healthy volunteers will participate in this biomedical research.

Distribution in groups

- 30 patients with type 2 diabetes and an indication for treatment with a GLP1 analogue (group 1)

- 30 patients with type 2 diabetes (control diabetic subjects) not treated with Incretins (group 2)

- 30 healthy subjects (non-diabetics) (group 3)

This study will investigate modifications in eating behaviour induced by Liraglutide in patients who start treatment with Victoza® and certain aspects, such as liking (hedonic characteristic of a food), wanting (desire to eat a given food) and salivation in response to the presentation of a food by taking measurements at D0 (before initiation of the treatment with Liraglutide in the group concerned) then at 15 days (except for the controls), 3 months and 9 months (only for controls).


Recruitment information / eligibility

Status Terminated
Enrollment 48
Est. completion date August 31, 2016
Est. primary completion date August 31, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

DIABETIC PATIENTS TREATED WITH LIRAGLUTIDE

- persons who have provided written informed consent

- aged > 18 years

- type 2 diabetes with HbA1C > 7%

- overweight (BMI > 27)

- normal renal function (creatinine clearance > 50ml/min)

- patients to be treated with Liraglutide (patients with type 2 diabetes with HbA1C > 7.5% and overweight or obesity, whose current treatment is insufficient to control the diabetes).

CONTROL DIABETIC PATIENTS

- persons who have provided written informed consent

- aged > 18 years

- type 2 diabetes with HbA1C > 7%

- overweight (BMI > 27)

- patients for whom treatment with Liraglutide is not indicated

- normal renal function (creatinine clearance > 50ml/min)

HEALTHY SUBJECTS

- persons who have provided written informed consent

- aged > 18 years

Exclusion Criteria:

DIABETIC PATIENTS TREATED WITH LIRAGLUTIDE

- type 1 diabetes

- decompensated congestive heart failure

- acute or chronic infection, progressive cancer, liver cirrhosis

- ongoing treatment with antibiotics

- smoking

- chronic alcohol abuse (>4 glasses a day)

- aversion to the products to be eaten or smelled

- poor understanding of the cognitive tasks requested

- treatment interfering with olfactogustatory performance, such as psychotropic, anti-emetic and anti-ulcer drugs

- persons without national health insurance cover

- persons under guardianship

- hypersensitivity to Liraglutide

- pregnancy, breastfeeding

- history of acute or chronic pancreatitis

- calcitonin level at selection = 50 ng/L

- liver disease, defined by a level of alanine aminotransferase (ALAT) = 2.5 times the upper limit of normal (ULN) for reference values

CONTROL DIABETIC PATIENTS

- type 1 diabetes,

- decompensated congestive heart failure,

- acute or chronic infection, progressive cancer, liver cirrhosis,

- ongoing treatment with antibiotics,

- smoking

- chronic alcohol abuse (> 4 glasses a day),

- aversion to the products to be eaten or smelled,

- poor understanding of the cognitive tasks requested,

- treatment interfering with olfactogustatory performance, such as psychotropic, anti-emetic and anti-ulcer drugs.

- persons without national health insurance cover

- persons under guardianship

HEALTHY SUBJECTS

- diabetes (type I and II)

- sensory disorders

- decompensated congestive heart failure,

- acute or chronic infection, progressive cancer, liver cirrhosis,

- ongoing treatment with antibiotics,

- smoking

- chronic alcohol abuse (> 4 glasses a day),

- aversion to the products to be eaten or smelled,

- poor understanding of the cognitive tasks requested,

- treatment interfering with olfactogustatory performance (psychotropic, anti-emetic, anti-ulcer drugs)

- persons without national health insurance cover

- persons under guardianship

- contra-indications to MRI, notably, but not limited to: pace maker, implantable cardiac defibrillators, neurostimulators, cochlear implants, certain implanted automated injection systems (insulin pumps), vascular intracerebral ferromagnetic clips, certain systems to regulate intravascular temperature, myopia requiring the patients to wear spectacle, history of stroke or transient ischemic attack (TIA), metallic foreign body, in particular intraocular or situated near high-risk zones (nervous system, vascular system), claustrophobia….

Study Design


Intervention

Drug:
Liraglutide

Other:
Observation alone


Locations

Country Name City State
France CHU de DIJON Dijon

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Modifications in wanting Up to 3 months
Secondary Modifications in gustatory performance Until 3 months
Secondary Modifications in liking Until 3 months
Secondary Modifications in salivation following the presentation of foods Until 3 months
Secondary Modifications in optimal preferences for sweet and fatty tastes Until 3 months
Secondary Anthropometric modifications Until 3 months
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revitaâ„¢ System in Treatment of Type 2 Diabetes N/A